Dr. Veerapol Khemarangsan, CEO of MEDEZE Group Public Company Limited (SET: MEDEZE), announced that on June 11, 2025, the company welcomed visitors to tour the Bang Rak Medical Center building. The facility is currently designing and is preparing for the Advanced Therapy Medicinal Products Sandbox (ATMPs Sandbox) project.
This initiative aims to develop groundbreaking advanced medical products for precision preventive medicine, focusing on personalized treatments. Notably, MEDEZE is the only private enterprise selected to join the ATMPs Sandbox as a provider of advanced testing, separation, cultivation, and storage of stem cells, as well as the assessment of NK cell (Natural Killer cell) potential.
The company will also offer hair follicle cell storage and robotic cell banking, placing it at the forefront of the biotech and stem cell banking industry. The project is set for completion within the next two months.
MEDEZE is currently awaiting procedural approval for every step of the process from the Department of Disease Control and must also pass the Food and Drug Administration (FDA) approval. There will be a press conference and the signing of a legally binding Memorandum of Agreement (MOA) between all parties involved. Initially, MEDEZE will be focusing its research and development on two areas:
1) Degenerative Disc Disease: Utilizing autologous adipose-derived stem cell therapy to regenerate tissue and mitigate disc degeneration, this non-surgical approach aims to reduce chronic back pain.
If successful, this would reduce dependency on imported titanium joints—currently valued at over THB 10 billion, as Thailand cannot produce them domestically—and significantly lower treatment costs, which typically reach nearly THB 100,000 per patient. Given the high prevalence of the disease, this could benefit a substantial number of patients.
2) Skin Diseases and Anti-Aging: Harnessing autologous adipose-derived stem cells for cell rejuvenation, wrinkle reduction, and deep skin restoration. If research and development succeed, this treatment could attract both local and international patients—particularly health tourists and the elderly—to seek advanced anti-aging and aesthetic treatments at Thai medical institutions.
MEDEZE aims to deliver research results for degenerative disc disease and skin disease/anti-aging by mid-2026 and plan to develop and register at least 2-3 new drugs. These initial solutions will pave the way for future research into kidney failure, lupus, psoriasis, liver disease, autoimmune diseases, and all kinds of inflammatory diseases, Dr. Veerapol commented.
Dr. Anek Mungaomklang, Deputy Director General of the Department of Disease Control, commented that the department’s goal is to establish the Bang Rak Medical Center, located in central Bangkok, as a benchmark for modern medical innovation in Thailand, and as a hub and model for future industry operators. The collaboration with MEDEZE is expected to be clarified within three months.
He also stressed that all approvals must proceed through the FDA and that the project will involve multi-party collaboration, including expert physicians, MEDEZE, and specialists.
The first medicines will be introduced at Vachira Phuket Hospital, the pilot site for the ATMPs Sandbox project. This will be a key step toward developing comprehensive advanced medical services and supporting the government’s policy of advancing Thailand as a regional medical hub.
